Physician profile
Lori King
NPI 1124595699
$974.29
in general payments reported to CMS, 2019-2025
19 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $316 · 2023: $96.55 · 2024: $177 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471 · Education: $41.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.12 |
| Education | $41.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $222.72 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $160.51 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $89.87 | 2021-2024 | Takhzyro |
| Astrazeneca Pharmaceuticals Lp | $72.26 | 2022-2024 | Breztri, Farxiga |
| Biocryst US Sales Co., LLC | $54.19 | 2024 | Orladeyo, Orladeyo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.21 | 2022-2025 | Caplyta |
| Dexcom, INC. | $50.91 | 2022-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $40.54 | 2021-2023 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $32.78 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $31.89 | 2022 | |
| Pfizer INC. | $30.58 | 2021 | |
| Astellas Pharma US INC | $29.25 | 2025 | Veozah |
| Actelion Pharmaceuticals US, INC. | $25.60 | 2024 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.56 | 2023 | Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $14.48 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $13.57 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $13.33 | 2023 | Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $12.91 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.